Projected inhibition of platelet aggregation with ticagrelor twice daily vs. clopidogrel once daily based on patient adherence data (the TWICE project).
Mar 17, 2015
Overview:Aim of the Study TWICE project study compared the anticipated inhibition of platelet aggregation (IPA) of ticagrelor twice-daily to clopidogrel once-daily using patients’ adherence data. Methods Using an electronically compiled dosing history, data of 5014 patients prescribed cardiovascular medications (primarily... more
Lorcanesin is accepted for weight loss
Apr 28, 2017
Overview:By Professor Juan Tamargo, Madrid, Spain In recent years, the only pharmacologic treatment available for obesity has been orlistat, but the drug produces a modest weight loss and is poorly tolerated due to gastrointestinal side effects. The Endocrinologic and Metabolic... more
The Growing Importance of Polypills in the Management of Cardiovascular Diseases
Nov 06, 2017
Overview:By Jose Maria Castellano, MD* The worldwide epidemic of cardiovascular disease sparked nearly 15 years ago the concept of a CV polypill. It seems counterintuitive that in the time of personalized medicine, a cardiovascular polypill would be deemed as one... more
Clopidogrel with aspirin in acute minor stroke or transient ischemic attack
Jul 17, 2013
Overview:BACKGROUND: Stroke is common during the first few weeks after a transient ischemic attack (TIA) or minor ischemic stroke. Combination therapy with clopidogrel and aspirin may provide greater protection against subsequent stroke than aspirin alone. METHODS: In a randomized, double-blind,... more
Polypill for Primary Prevention: Largest-Yet Reductions in BP, Cholesterol in Small UK Trial
Apr 28, 2017
Overview:By Professor Juan Tamargo, Madrid, Spain The effects of a polypill containing three BP-lowering medications (amlodipine 2.5 mg, losartan 25 mg and hydrochlorothiazide 12.5 mg) along with the lipid-lowering simvastatin 40 mg was evaluated for the primary prevention of cardiovascular... more
HORIZON-AMI prompts FDA approval for ION Stent System
Apr 28, 2017
Overview:By Professor Juan Tamargo, Madrid, Spain The FDA approved the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System and TAXUS® Liberte® Paclitaxel-Eluting Coronary Stent Systems for use in patients experiencing an acute MI. The FDA based its approval on a review... more
A Randomized and Clinical Effectiveness Trial Comparing Two Pharmacogenetic Algorithms and Standard Care for Individualizing Warfarin Dosing (CoumaGen-II)
May 17, 2012
Overview:Background Clinical management of warfarin therapy is difficult because of the narrow therapeutic index and marked inter-patient variability in drug pharmacokinetics and pharmacodynamics, which lead to unpredictable and variable (up to 10-fold or greater) dosing requirements. This often results in under-... more
FDA approval for Jentadueto (metformin plus linagliptin)
Apr 28, 2017
Overview:By Professor Juan Tamargo, Madrid, Spain. The FDA has approved Jentadueto, a combination of metformin plus linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor for type 2 diabetes. JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who need to... more
The Complex Management of End-Stage Heart Failure: The Importance of Quality of Life
Mar 28, 2018
Overview:Hector Ventura, MD* Heart failure affects nearly 6 million worldwide and is associated with high morbidity and mortality. Because of the natural progression of the disease, approximately 10% of patients suffer from advanced heart failure. These patients have debilitating symptoms... more
Rivaroxaban not FDA approved for the risk reduction of secondary CV events in patients with ACS
Apr 28, 2017
Overview:By Professor Juan Tamargo The FDA's Cardiovascular and Renal Drugs Advisory Committee declined to approve (6-4, with one abstention) to approve rivaroxaban for use in acute coronary syndromes (ACS). Despite positive results from the global, phase III ATLAS ACS 2-TIMI... more